NCT01258933View on ClinicalTrials.gov

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

PHASE2TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

July 6, 2011

Primary Completion Date

October 18, 2024

Study Completion Date

October 18, 2024

Conditions

LeukemiaLymphoma

Interventions

DRUG

Ofatumumab

300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

GlaxoSmithKline

All Listed Sponsors

collaborator

GlaxoSmithKline

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER